CoChat

Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

The proteasome has emerged as a novel target for antineoplastic treatment of hematological malignancies and solid tumors, including those of the central nervous system. To identify cell death pathways activated in response to inhibition of the proteasome system in cancer cells, we treated human SH-SY5Y neuroblastoma cells with the selective proteasome inhibitor (PI) epoxomicin (Epoxo). Prolonged exposure to Epoxo was associated with increased levels of poly-ubiquitinylated proteins and p53, release of cytochrome c from the mitochondria, and activation of caspases. Analysis of global gene expression using high-density oligonucleotide microarrays revealed that Epoxo triggered transcriptional activation of the two Bcl-2-homology domain-3-only (BH3-only) genes p53 upregulated modulator of apoptosis (PUMA) and Bim. Subsequent studies in PUMA- and Bim-deficient cells indicated that Epoxo-induced caspase activation and apoptosis was predominantly PUMA-dependent. Further characterization of the transcriptional response to Epoxo in HCT116 human colon cancer cells demonstrated that PUMA induction was p53-dependent; with deficiency in either p53 or PUMA significantly protected HCT116 cells against Epoxo-induced apoptosis. Our data suggest that p53 activation and the transcriptional induction of its target gene PUMA play an important role in the sensitivity of cancer cells to apoptosis induced by proteasome inhibition, and imply that antineoplastic therapies with PIs might be especially useful in cancers with functional p53.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1209974

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Research works printed but not linked: 1

  1. Adams J . (2004b). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349–360. · DOI · Paper page

Cited by

See all 99

Metadata

Authors
Concannon, C. G., Koehler, B. F., Reimertz, C., Murphy, B. M., Bonner, C., Thurow, N., Ward, M. W., Villunger, A., Strasser, A., Kögel, D., & Prehn, J. H. M.
Affiliations
  • Royal College of Surgeons in Ireland (IE)
  • Goethe University Frankfurt (DE)
  • Innsbruck Medical University (AT)
  • Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author
Prehn, J H M
Venue
Oncogene
Published
2006-09-18
Volume
26
Issue
12
Pages
1681-1692
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2056205420
Cited by
95
References
55
Citations by year
2026: 1 · 2025: 2 · 2024: 7 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 6 · 2013: 4 · 2012: 6
FWCI
4.48
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Science Foundation Ireland
  • Deutsche Forschungsgemeinschaft
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
proteasome inhibition, apoptosis, p53, PUMA, building information modeling, BH3-only proteins, epoxomicin, caspase activation, cytochrome c release, neuroblastoma, colon cancer, transcriptional regulation, antineoplastic therapy, p53-dependent apoptosis
MeSH terms
Base Sequence, Humans, Molecular Sequence Data, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Apoptosis, Protein Folding, DNA Primers, Oligonucleotide Array Sequence Analysis, Cell Line, Tumor, Apoptosis Regulatory Proteins, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. https://app.cochat.ai/papers/10.1038/sj.onc.1209974
The paper
Concannon, C. G., Koehler, B. F., Reimertz, C., Murphy, B. M., Bonner, C., Thurow, N., Ward, M. W., Villunger, A., Strasser, A., Kögel, D., & Prehn, J. H. M. (2007). Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene. https://doi.org/10.1038/sj.onc.1209974

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.